First molecular map of the entire retina is not far away

Article

Researchers at the Moran Eye Centre are using transmission electron microscopes (TEMs) to develop TEM-compatible molecular probes with software that will tag cells with a molecular signature, creating 'colour' TEM imaging.

Researchers at the Moran Eye Centre are using transmission electron microscopes (TEMs) to develop TEM-compatible molecular probes with software that will tag cells with a molecular signature, creating 'colour' TEM imaging.

The researchers are reported to be on the verge of revealing the first molecular map of the entire retina and neuronal networks in both a mammalian retina and genetic models of retinal degeneration. James Anderson, the lead researcher said: "This technology lets the neuroscience field build circuitry blueprints for healthy neural tissues. We can compare diseased tissues to these blueprints to understand how they rewire the brain and use them to evaluate the effectiveness of treatments which aren't detectable with other methods."

These technical advances have reduced the time it takes to process high-speed colour ultrastructure mapping of the brain regions down to a few months. Robert Marc, Ph.D., Director of Research for the Moran Eye Center at the University of Utah and colleagues have been working on this project for eight years. They have refined the software and molecular tools to where they are now able to share them globally. "This changes the playing field for building brain maps from a few specialized laboratories to the desktops of biologists world-wide," said Marc.

Click here to read the full paper.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.